Alzheimer's Research & Therapy is a leading peer-reviewed journal published by BMC, dedicated to advancing our understanding of Alzheimer's disease and other neurodegenerative disorders. As an Open Access journal since 2009, it ensures that vital research findings are freely accessible to the global community, facilitating collaboration and innovation in the field. The journal's commitment to quality is evident in its impressive impact factor and its prestigious ranking in the Q1 quartile across multiple categories including Cognitive Neuroscience and Neurology. With a Scopus rank placing it in the top tier of both Neuroscience and Neurology disciplines, Alzheimer's Research & Therapy serves as a crucial platform for researchers, clinicians, and students who seek to contribute to the fight against Alzheimer's and related disorders. The journal covers a wide range of topics and actively encourages submissions that explore therapeutic strategies and innovative research methodologies, enriching the scientific dialogue in this vital area of health.

Noropsikiyatri Arsivi-Archives of Neuropsychiatry is a prominent scholarly journal dedicated to advancing knowledge in the fields of neuropsychiatry and mental health. Published by the Turkish Neuropsychiatry Association, this journal aims to disseminate high-quality research that contributes to a deeper understanding of psychiatric disorders, innovative treatment modalities, and interdisciplinary approaches in neuroscience. Based in Turkey, the journal has been in circulation since its inception, with a rich history reflecting its commitment to addressing contemporary issues in mental health care. It is currently indexed under Scopus, with notable rankings in both Psychiatry and Mental Health (Rank #378/567, 33rd Percentile) and General Neuroscience (Rank #97/113, 14th Percentile), highlighting its increasing relevance and impact in the academia. Although it is not currently an open access journal, its contributions remain vital for researchers, professionals, and students who wish to stay abreast of the latest developments and research in neuropsychiatry.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, published by MARY ANN LIEBERT, INC, stands as a premier academic journal dedicated to advancing the field of pediatric psychopharmacology. With a rich history of publication spanning from 1990 to 2024, this journal presents cutting-edge research that informs clinical practices and policy decisions impacting the mental health of children and adolescents. Ranked in the Q2 category for both Pediatrics, Perinatology and Child Health and Pharmacology (medical) as of 2023, it reflects its critical contribution to these fields, along with a respectable Q3 status in Psychiatry and Mental Health. Researchers and practitioners benefit from the journal's rigorous peer-reviewed articles, which delve into the efficacy, safety, and ethical implications of pharmacological treatments tailored for young populations. Although the journal does not currently offer Open Access, it remains a vital resource for anyone engaged in child and adolescent health research and treatment strategies. Its commitment to fostering dialogue and innovation in psychopharmacology ensures its pivotal role in shaping future standards and practices in this essential area of medical science.

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

Pediatric Neurology, a prestigious journal published by Elsevier Science Inc, is a leading resource in the field of child neurology and developmental neurosciences. With an impressive impact factor and categorization in the Q1 and Q2 quartiles across several relevant fields, including Pediatrics, Neurology, and Developmental Neuroscience, this journal is essential for researchers and healthcare professionals focused on pediatric neurological disorders. Since its inception in 1985, it has provided a platform for high-quality research, clinical studies, and reviews that drive advancements in diagnosis, treatment, and understanding of neurological conditions in children. Although the journal does not currently offer open access, it maintains a robust reputation in the academic community, bolstered by its prominent ranking in Scopus metrics. By engaging with the latest findings published in Pediatric Neurology, readers will gain vital insights that contribute to improving pediatric healthcare outcomes in neurology and neuroscience.

The Journal of Attention Disorders is a premier peer-reviewed publication dedicated to advancing the understanding and treatment of attention-related disorders. Published by SAGE Publications Inc, this esteemed journal has become a vital resource in the fields of Clinical Psychology and Developmental and Educational Psychology, consistently ranking in the Q1 quartile for both categories as of 2023. With a significant impact factor and a commendable Scopus rank—#37 in Developmental and Educational Psychology and #34 in Clinical Psychology—this journal fosters innovative research and evidence-based practices that contribute to the mental health field. Since its inception in 1996, the Journal of Attention Disorders has provided a platform for the latest findings and discussions, supporting researchers, practitioners, and students alike. While the journal remains non-open access, it ensures rigorous dissemination of crucial information, solidifying its importance in shaping future research and best practices concerning attention disorders.

Journal of Alzheimer's Disease Reports, published by IOS PRESS, is an essential open-access platform dedicated to advancing research in the fields of clinical psychology, geriatrics, gerontology, neuroscience, and psychiatry. Since its inception in 2017, this journal has rapidly gained recognition, achieving a commendable status reflected in its 2023 category quartiles, notably ranking Q2 in Clinical Psychology and Psychiatry and Mental Health. With a sustained commitment to disseminating high-quality research and facilitating collaboration among scientists, the journal offers insights into the critical aspects of Alzheimer's disease and related cognitive disorders. Given its positions in the Scopus ranks, it serves as a crucial resource for academics and practitioners alike, empowering them to contribute effectively to the ongoing discourse in cognitive health. The journal embraces open access, ensuring that all research findings are freely available to the global community, thereby enhancing visibility and engagement. With a focus on fostering innovation and knowledge transfer, Journal of Alzheimer's Disease Reports is poised to make an enduring impact in the field of dementia research.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

Parkinson's Disease is a prestigious open access journal dedicated to advancing the field of neurology with a special emphasis on Parkinson's disease and related movement disorders. Published by Hindawi Ltd, the journal has established itself as a vital resource since its inception in 2008, transitioning to an open access model in 2010. Featuring the ISSN 2090-8083 and E-ISSN 2042-0080, it has rapidly gained traction in the academic community, currently ranked Q2 in clinical neurology and psychiatry in the 2023 category quartiles, highlighting its significance and quality within the field. With Scopus rankings placing it in the top percentiles for neuroscience and psychiatry, it provides researchers, healthcare professionals, and students with cutting-edge research, reviews, and clinical studies. Situated in London, England, this journal encourages submissions that contribute to the understanding and management of Parkinson's disease, showcasing the latest findings and fostering collaboration among researchers worldwide.